Oncolytic Newcastle disease virus (NDV) replicates selectively in most human tumor cells but not in normal cells. The relationship between tumorigenesis and the selective susceptibility of most tumor cells to oncolytic NDV replication is poorly understood. A multistage skin carcinogenesis model derived from non-tumorigenic HaCaT cells was used to systematically investigate the molecular mechanisms involved in the oncolytic NDVsensitivity associated with tumorigenic transformation. No significant differences in interferon signaling were observed between the virus-sensitive tumor cells and the virus-resistant non-tumorigenic parental cells. Oncogenic H-Ras, which had been used for tumorigenic transformation, was shown to be necessary for virus replication but was not sufficient to render cells susceptible to NDV replication. By using an siRNA screening approach to search for virus-sensitizing genes in the tumorigenic cells, we could identify the small GTPase Rac1 as an oncogenic protein that is essential for NDV replication and anchorage-independent growth in tumorigenic cells. Furthermore, Rac1 expression was sufficient to render non-tumorigenic cells susceptible to NDV replication and to oncolytic cytotoxicity. This study establishes Rac1 as a link between tumorigenesis and oncolytic virus sensitivity in the HaCaT multistage skin carcinogenesis model.
Introduction
Newcastle disease virus (NDV) is an avian paramyxovirus with innate antineoplastic properties (Wheelock and Dingle, 1964; Cassel and Garrett, 1965) . NDV preferentially replicates in a variety of human tumor cells but not in normal cells (Reichard et al., 1992) . As NDV is nonpathogenic in humans and is associated with only a few minor symptoms, several NDV strains are under clinical evalulation for anticancer treatment (Sinkovics and Horvath, 2000; Pecora et al., 2002; Hotte et al., 2007) . The tumor-selective replication of oncolytic RNA viruses such as NDV or vesicular stomatitis virus (VSV) has been proposed to be related to tumor-specific defects in the cellular antiviral defense. These defects are thought to be acquired during the process of tumorigenic transformation and are probably linked to enhanced proliferation and tumor cell survival (Stojdl et al., 2000) . However, the precise mechanisms rendering tumor cells susceptible to oncolytic replication are not fully understood and need to be analyzed in more detail.
In normal cells, infection and cytosolic replication of RNA viruses like NDV activate a type I interferon (IFN) response leading to the inhibition of viral replication and viral spread. The induction of an antiviral state is maintained by the expression of a variety of IFNstimulated factors with antiviral activity, such as the well-studied intrinsic antiviral enzymes myxovirus resistance proteins (Mx), 2 0 -5 0 -oligoadenylate synthetases (OAS) or protein kinase R (PKR) . In tumor cells, lowered interferon secretion combined with weak basal IFN expression and impaired induction of IFN-induced antiviral proteins have been shown to correlate with efficient NDV replication (Fiola et al., 2006; Krishnamurthy et al., 2006; Wilden et al., 2009) . Further, it has been shown that oncogenic Ras activity can mediate oncolytic virus susceptibility for viruses like reovirus or VSV by interfering with antiviral responses (Strong et al., 1998; Noser et al., 2007) . In addition, efficient translation of VSV was shown to depend on tumor-specific defects in translational control (Balachandran and Barber, 2004) . For oncolytic NDV, it was observed that N-Ras transformation of human fibroblasts rendered cells a thousand-fold more sensitive to NDV-mediated cytoxicity than normal fibroblasts (Lorence et al., 1994) . However, the molecular basis for the Ras-induced NDVsusceptibility in tumor cells was not investigated further.
To better understand the tumor-specific susceptibility of cells to oncolytic viruses, this study was aimed to systematically investigate NDV-sensitizing factors or pathways connected with tumorigenic transformation. Therefore, we chose to use a cellular model for transformation comprising of two closely related cell lines-one being non-NDV-susceptible and non-tumorigenic, the other being NDV-susceptible and tumorigenic.
The requirements for such a cellular system were met by the well-characterized multistep skin carcinogenesis HaCaT model (Boukamp et al., 1988 (Boukamp et al., , 1990 Mueller et al., 2001 ). For the model in this study, we used the immortal but non-tumorigenic parental HaCaT cell line that was described previously to be resistant to oncolytic NDV replication (Puhler et al., 2008) and the c-H-Rastransformed and highly malignant A5-RT3 cells (RT3) (Boukamp et al., 1988; Mueller et al., 2001) . Our initial investigations with this epithelial cancer cell line model focused on proposed virus-sensitizing pathways and yielded unexpected findings described here. These findings subsequently led us to establish a unique siRNA-based screen to identify novel cellular factors that link tumorigenesis with sensitivity to oncolytic viruses.
By using this screening approach we aimed to identify cellular proteins that are necessary for infection and replication of oncolytic NDV. It was possible to indirectly identify genes associated with tumorigenesis by screening for genes that are essential for tumorselective replication of oncolytic viruses. Such tumorspecific, NDV-sensitizing genes constitute potential targets for anticancer treatment or biomarkers for efficient oncolytic NDV replication.
The use of this HaCaT-derived cell line model allowed us to screen for virus-sensitizing genes in a tumorigenic cell line and subsequently to characterize the NDVsensitizing features of any hits in the non-susceptible counterpart cell line.
Recently, we described the generation of a transgeneexpressing recombinant oncolytic NDV based on a naturally oncolytic strain (Puhler et al., 2008) . By using such a reporter gene-carrying virus, it was possible to quantitatively monitor viral replication in a multiwell screening approach.
With this new screening approach we identified several candidates with NDV-sensitizing properties. The screening candidate Rac1 was further validated as a NDV-sensitizing gene that is also involved in maintaining anchorage-independent growth.
Results
Correlation of malignancy and sensitivity to oncolytic NDV replication in a HaCaT-derived cell line model The HaCaT model represents multiple stages of skin carcinoma development and progression. We first tested whether this tumor model could also be applied as a model for oncolysis and whether malignant progression correlates with enhanced susceptibility to oncolytic NDV replication. Transformation of HaCaT cells with oncogenic c-H-ras has been shown to induce benign or malignant tumorigenic growth in vivo (Boukamp et al., 1990) . Subsequent in vitro cloning did not select for increased malignant phenotypes. In contrast, serial in vivo passaging of a benign HaCaT-Ras clone induced tumorigenic progression to a highly malignant and even metastatic phenotype (Fusenig and Boukamp, 1998; Mueller et al., 2001 ). We performed a colony-forming assay and were able to isolate a subclone (K1) of the highly tumorigenic RT3 cells. K1 was observed to show a characteristic enhanced colony-forming ability in soft agar (Figures 1a and b) . Figure 1b shows a colony formation assay for the three cell lines that were chosen for further studies. To investigate whether enhanced growth of RT3 K1 cells in soft agar correlated with an increased tumorigenic potential in vivo, tumor growth of the parental HaCaT cells, the RT3 tumor cells and the derived RT3 K1 cells were compared after inoculation of equal numbers of cells subcutaneously into nude mice. While the parental HaCaT cells remained nontumorigenic and thus served as a negative control (Figure 1c) , the RT3 cells formed rapidly growing tumors. The RT3 K1 subclone grew even faster than their parental cell line. Within one week RT3 K1-derived tumor size tripled, whereas the original RT3 cells showed only a 2-fold increase in tumor size within the same time period. Therefore, RT3 K1 cells not only featured an enhanced anchorage-independent growth but also an increased malignancy in vivo compared with the parental RT3 cell line. Enhanced tumor growth of RT3 K1 cells could not be explained by a faster growth in vitro compared with the RT3 cells (data not shown).
HaCaT, RT3 and RT3 K1 cells were subsequently characterized for NDV-susceptibility. We aimed to determine whether the tumorigenic RT3 cells were susceptible to oncolytic NDV and in addition whether the more tumorigenic subclone RT3 K1 differed from parental RT3 in both its tumor growth potential, as well as a higher susceptibility to oncolytic NDV. Therefore, HaCaT, RT3 and RT3 K1 cells were infected with a recombinant NDV designed to drive expression of the reporter gene EGFP to monitor viral protein expression after viral infection. The cells were infected at a low (Boukamp et al., 1990; Fusenig and Boukamp, 1998; Mueller et al., 2001) . cell lines (Figure 1e ). The increased NDV-susceptibility of the tumorigenic RT3 K1 cells was followed by an enhanced NDV-mediated oncolysis compared with their parental cell line. Whereas more than 80% of HaCaT cells were still viable at an MOI of 0.1, the majority of the RT3 K1 cells was killed at MOIs as low as 0.01 after 48 h. The RT3 cells again showed an intermediate phenotype.
To prove that NDV is able to productively infect all three cell lines and to correlate the results of viral transgene infection experiments with virus production, NDV titer in supernatants were monitored in a time course infection experiment ( Figure 1f ). After 16 h no significant differences were observed. However, after multiple viral replication cycles (24 h) the viral titer in the supernatant of the tumorigenic RT3 K1 cells was about a thousand-fold increased compared with the non-tumorigenic HaCaT cells. RT3 cells exhibited an intermediate phenotype. The saturation in virus production in the RT3 K1 cells is limited by the cytotoxicity of the virus and the death of the virus-producing cells. Figure 1g shows a western blot of NDV proteins after infection of the cells at an MOI of 1. At this high MOI, NDV infection clearly occurred in all three assayed cell lines and viral protein expression was detectable at 6-8 h post-infection with no major observed difference between the cells. Mechanisms for cell binding, entry of the virus and initial viral protein synthesis, therefore, seemed to be intact in all cells.
Taken together, we here describe a human cell line model in which tumorigenesis correlates with susceptibility to oncolytic NDV. Increased malignancy of RT3 K1 cells compared with RT3 and HaCaT cells correlate with enhanced NDV-sensitivity, NDV-mediated cell death and NDV production and release. These cell lines, therefore, provide an appropriate tool to investigate the molecular differences that drive both tumorigenesis and sensitivity to oncolytic NDV.
NDV replication in tumorigenic RT3 K1 cells is neither caused by major defects in the induction of an IFN response nor by eIF-2Be-mediated dysregulated translational control It has been proposed that an impaired antiviral defense is a reason for the tumor-selective replication of NDV in human tumor cells (Fiola et al., 2006; Krishnamurthy et al., 2006) . In normal human cells, NDV infection leads to the activation of the IFN pathway that results in the induction of an antiviral state of the infected and neighboring cells and consequently prevents virus production and spread. We therefore analyzed and compared the induction of the IFN signaling pathway in the HaCaT-derived cell line model after NDV infection. Figure 2a shows the induction of IFN type I activity in the three cell lines after infection with a high MOI. Clearly, all three cell lines react to the NDV infection by secreting interferon. The induction of IFN appeared to be even stronger in RT3 and RT3 K1 cells as compared with the non-tumorigenic HaCaT cells. This experiment proved that the virus-induced secretion of interferon was still intact in all cell types. To determine whether type I IFN can trigger an antiviral response in these cells, an indirect assay was used. Because HaCaT cells do not show severe virus-induced cell death, only RT3 K1 cells were pretreated with recombinant human interferon and subsequently challenged with NDV at low MOI and monitored for cell survival after 48 h (Figure 2b ). The increased cell survival observed indicates that interferon is able to prevent viral cytotoxicity in RT3 K1 cells. Both IFNa and IFNb mediated protection in the RT3 K1 cells. In addition, single cell analysis by fluorescence microscopy illustrates that NDV-EGFP replication can be dramatically diminished in the tumorigenic HaCaT cell lines RT3 and RT3 K1 when the cells are pretreated with recombinant IFNa (Supplementary Figure S1) . In summary, these experiments show that there are no gross defects in IFN type I secretion and IFN-mediated induction of an antiviral state in the tumorigenic HaCaT cells.
To further analyze the IFN pathway in these cells, we studied the activation and induction of STAT1 and 2 which are components of the JAK-STAT pathway and are activated as a consequence of IFN binding to its cell surface receptor (Darnell et al., 1994) . On infection with high MOI of NDV, both STAT1 and 2 were phosphorylated within 16 h (Figure 2c ) although kinetics and magnitudes of activation and induction were reduced in the tumorigenic cells. However, activation could clearly be shown in all three cell lines. This finding excludes a general defect in signal transduction down to STAT1 and 2.
IFN signaling leads to transcriptional activation of various genes that have antiviral functions, such as PKR, OAS1 or MxA (reviewed in Stark et al., 1998) . A defect in that signal transduction pathway is expected to result in a lack of IFN-mediated gene induction. Therefore, we measured mRNA and protein induction of these three genes after high MOI infection with NDV (Figures 2c and  d) . After NDV infection, a clear induction of all genes could be observed in all three cell lines as early as 6 h postinfection and protein expression of both OAS1 and MxA could be detected. MxA protein expression was reduced and delayed in the tumorigenic cell lines compared with HaCaT cells. These results show that interferon signaling and antiviral gene inductions are delayed but not generally defective in the tumorigenic cells.
The cytosolic dsRNA sensor PKR is a central component of the antiviral response. Ras transformation has been described to inhibit PKR phosphorylation and, therefore, enable replication of oncolytic viruses such as reovirus (Mundschau and Faller, 1992; Strong et al., 1998) . Figure 2c shows the phosphorylation of PKR and demonstrates that in the cell model used here, transformation did not generally inhibit PKR phosphorylation. Therefore, unlike reovirus, the tumorspecific NDV replication must be caused by a different mechanism than Ras-mediated inhibition of PKR phosphorylation.
For VSV, another oncolytic RNA virus, the reason for the tumor-selective replication is thought to be not only a defective IFN response but also a deregulated translational control caused by overexpres- possibility of elevated elF-2B activity as a cause for the selective replication of NDV in RT3 K1 cells. Together, these data showed no evidence for a general defect of antiviral response in these tumorigenic cell lines.
Ras is required for oncolytic NDV-sensitivity in tumorigenic RT3 K1 cells but is not sufficient to mediate virus susceptibility in Ras-transformed HaCaT cells Lorence et al. (1994) showed that non-NDV-susceptible human fibroblasts were thousand times more sensitive to This was shown microscopically using recombinant NDV-expressing the reporter gene EGFP (Figure 3c ) as well as quantitatively using NDV-expressing luciferase ( Figure 3b ). Therefore, Ras is necessary for the efficient replication of NDV in these cells.
Initial inhibitor experiments for Ras-effectors were performed using the PI3K inhibitor LY294002 and MEK 1/2 inhibitor U0126. The results show that both PI3K and MEK pathways potentially contribute to the effect of Ras on NDV replication (Supplementary Figure S2) .
Having shown that Ras is essential for NDV replication in the RT3 K1 cells, we wanted to determine whether Ras alone is also sufficient to render the nontumorigenic HaCaT cells NDV-susceptible. HaCaT cells were stably transfected with oncogenic c-H-RasV12. In parallel the HaCaT-Ras II4 clonal cell line that forms invasive skin carcinomas in nude mice but is less malignant than the RT3 cells was included in the experiment (Boukamp et al., 1990 ). Figure 3d shows increased H-Ras protein levels in these cells. Elevated Erk-phosphorylation as well as colony formation in soft agar (Figure 3d and e) were used as markers for Ras activation and functionality in these cells.
As shown in Figure 3f , infection of these cells with a NDV-luciferase reporter virus did not lead to significant luciferase signals similar to the resistant parental HaCaT cells. RT3 K1 cells were used as a positive control that allows for NDV replication, which results in a high luciferase signal. Although all HaCaT-Ras cells clearly overexpress Ras, they were not susceptible to NDV replication. Therefore, Ras alone is not sufficient to convert the cells to an NDV-susceptible phenotype.
An siRNA screen identifies Rac1 as a sensitizer to NDV replication in tumor cells The viral life cycle of NDV is not completely understood and so far there have been no specific hints of tumorrelated or deregulated cellular factors or functions that are hijacked and used for viral RNA/protein trafficking within the infected cells. Knockdown of Ras in tumorigenic RT3 K1 cells led to a dramatic decrease in viral replication. Ras proteins are known to be localized and activated on the plasma membrane, endosomes and other intracellular membranes, for example, ER and Golgi (Hancock, 2003) . To reveal Ras-related or Ras-independent NDV-sensitizers in the tumorigenic RT3 K1 cells that may also be drivers of tumorigenesis, an siRNA-based screen of genes that are known or predicted to participate in membrane trafficking/remodeling was performed.
After treatment with the siRNA library in a wellbased approach, the cells were infected with NDVluciferase and tested for inhibition of virus replication using a luciferase assay. The screening included 112 genes and was performed twice. In Figure 4a , the candidate genes are shown, those which induced X50% reduction of viral replication after siRNA-mediated knockdown in the RT3 K1 cells. The cell viability was 475% (Figure 4a ) and thus, cytotoxicity caused by siRNA transfection could be excluded as a reason for the reduced viral luciferase activity for all of these hits. Altogether, from the 112 genes studied, knockdown of 17 genes resulted in a decrease of more than 50% NDV replication and knockdown of five genes resulted in an increased NDV replication by more than 1.5-fold (data not shown). One of the siRNA screening candidates reducing NDV replication was the Rho GTPase Rac1. The inhibitory effect on NDV replication after knockdown of Rac1 was validated with single Rac1 siRNAs. Figure 4b shows the knockdown of the protein in the RT3 K1 cells after treatment with individual siRNAs. Rac1 knockdown with two different siRNAs led to significant inhibition of viral replication and could be confirmed both microscopically with NDV-EGFP ( Figure 4c ) and quantitatively with NDV-luciferase (Figure 4d) .
We conclude that an siRNA screen is suitable to identify several candidates, including Rac1, as NDVsensitizing genes in RT3 K1 cells. Furthermore, specific knockdown of Rac1 significantly inhibited NDV replication. Therefore Rac1 is an essential protein for efficient replication of oncolytic NDV in the tumorigenic cells. Rac1 and oncolytic NDV J Puhlmann et al
Rac1 is necessary and sufficient for oncolytic NDV replication in a multistage tumorigenesis model To further support that Rac1 serves as a sensitizer to NDV, Rac1 was inhibited by a small molecule inhibitor NSC 23766. RT3 K1 cells were pretreated with the inhibitor and subsequently infected with luciferaseexpressing NDV in presence of the inhibitor. Figure 5a shows a dramatic reduction in viral replication as measured by the luciferase transgene expression. After treatment with 100 mM Rac1 inhibitor, viral luciferase activity was reduced to background levels of nonsusceptible and non-tumorigenic HaCaT cells. Cell viability was not seriously affected and therefore could not account for reduced luciferase signals (data not shown). These results proved that Rac1-activity was essential for viral replication.
A dominant negative mutant of Rac1 (Rac1T17N; Gao et al., 2004) was used to further confirm this observation. Overexpression of Rac1T17N in the RT3 K1 cells (Figure 5b ) not only negatively influenced NDV replication (Figure 5c ) but also led to an inhibition of anchorage-independent growth of RT3 K1 cells (Figure 5d ). These findings establish Rac1 as a protein whose activity is critical for both oncolytic virus sensitivity and autonomous growth behavior.
As Ras alone was not sufficient to render HaCaT cells susceptible to NDV, we decided to test whether Rac1 may have the ability to convert resistant HaCaT cells into NDV-susceptible cells. Therefore, we stably transfected HaCaT cells with Rac1wt (Figure 5e ). HaCaT Rac1wt (pool) cells were then infected with NDVluciferase and assayed for luciferase expression and cytotoxicity. In contrast to H-RasV12, Rac1-overexpression led to a significant increase in viral replication in the cell pool (Figure 5f ) accompanied by increased oncolysis (Figure 5g ). Therefore, Rac1 is able to drive NDV replication in a resistant non-tumorigenic cell line. As shown in Figure 5e , the magnitude of Rac1 overexpression was not great, thus the positive effect of Rac1 on the NDV replication may be underestimated. When individual cells were microscopically analyzed (Figure 5h) , there was clearly a colocalization of NDV replication with Rac1-overexpressing cells. NDV protein expression was almost exclusively (82% of EGFP positive cells) seen in Rac1-overexpressing cells strongly suggesting that NDV preferentially replicated in the Rac1-overexpressing cells.
In summary, we conclude that in addition to oncogenic Ras, Rac1 is an essential component for oncolytic NDV replication in tumorigenic RT3 K1 cells. Furthermore, in contrast to Ras, Rac1 expression is also able to promote viral replication in otherwise resistant non-tumorigenic HaCaT cells.
Discussion
NDV features a natural preference for replicating in most tumor cells but not in normal cells. Similarly to VSV (Stojdl et al., 2000) , the tumor-selective replication of NDV is believed to be a result from defects in transformed cells which prevent them from mounting an IFN-induced antiviral defense (Krishnamurthy et al., 2006; Wilden et al., 2009 ). The HaCaT model used here has proved to be a very powerful tool to identify contributors to the tumor-selective NDV replication. To the best of our knowledge, such a model, consisting of a pair of human epithelial cell lines with the same genetic background but different tumorigenicity and different sensitivity to oncolytic virus, has not previously been described.
Our investigations concerning dysregulation of known oncolytic virus-sensitizing factors or pathways did not reveal severe tumor-specific defects in either the translational control or in the IFN response. However, a delayed IFN response was observed at the level of the JAK/STAT signal transduction cascade and affecting the induction kinetics and expression levels of antiviral genes like MxA in the tumorigenic HaCaT cells. The significance of this finding with regard to NDVsusceptibility is currently unknown.
Apart from defects in antiviral defense, it had been shown that oncogenic Ras activity can mediate oncolytic virus susceptibility (Lorence et al., 1994; Bergmann et al., 2001; Farassati et al., 2001; Norman et al., 2004; Smith et al., 2006; Noser et al., 2007) .
We provide evidence here that siRNA-mediated HRas depletion does indeed render RT3 K1 cells nonsusceptible to NDV. In the reverse experiment, overexpression of oncogenic Ras in HaCaT cells alone as well as Ras transformation with subsequent in vivo tumor growth (II4 cells) was not sufficient to induce NDV-susceptibility in this cell line. These results strongly argue that additional factors or pathways are critical and are required to promote susceptibility to oncolytic NDV, either with or without the participation of Ras.
The correlation between susceptibility and increased malignancy observed in this model offers the chance to identify virus-sensitizing genes that are simultaneously connected with tumorigenesis. Indeed, by applying an siRNA-based screening for tumor-specific NDV-sensitizing factors in the tumorigenic NDV-susceptible RT3 K1 cells and using a library comprising of genes which participate in membrane trafficking/remodeling, we identified a number of hits that reduced viral replication to a level of at least 50%. Several of these hits, such as the RhoGTPase RhoA (Khosravi-Far et al., 1995) or the serine/threonine protein kinase Pak1 (Tang et al., 1999) are also potentially linked to tumorigenesis and, therefore, warrant further in-depth analysis. A schematic diagram illustrating the relationship of the small GTPase-related genes that were identified in this study to affect oncolytic NDV replication is shown in Supplementary Figure S5 .
Here, we focused on the Rho GTPase Rac1 because it is a pleiotropic regulator of multiple cellular functions including actin cytoskeletal reorganization, gene transcription and cell migration (Bosco et al., 2009) . As viruses can manipulate or make use of the cytoskeletal network of actin filaments during their life cycles, (virus-induced) Rac1 activity has been linked to viral infection or protein trafficking processes as well as the spread of several viruses causing severe human diseases, for example, HIV (Lu et al., 1996) , Ebola (Saeed et al., 2008) , HSV-1 (Hoppe et al., 2006) , HBV (Gros et al., 2008) and paramyxoviruses, for example, Hendra virus (Schowalter et al., 2006) . From rodent experiments Rac1 is known to have oncogenic activity and to be involved in tumorigenesis (Kissil et al., 2007) . Co-expression of activated Rac1 enhanced oncogenic Ras-induced morphologic transformation as well as frequency and size of Ras-transformed colonies in soft agar in NIH 3T3 cells (Khosravi-Far et al., 1995) . Rac1-promoted malignant phenotypes of skin keratinocytes were shown in a HRas-transformed mouse squamous cell carcinoma cell line. Expression of DN Rac1T17N led to a decrease in several markers of malignancy, including colony formation, migration and in vivo tumor growth (Kwei et al., 2006) . Chan et al. (2005) describe the role of Rac1 in human tumor cell invasion and recently a critical function for Rac1 in tumor progression of human colorectal adenocarcinoma cells was reported (Espina et al., 2008) .
Rac1 was identified for the first time in this study to be critical for the replication of oncolytic NDV. Its NDV-sensitizing activity in RT3 K1 cells was confirmed by three independent experimental approaches using (1) Rac1-specific siRNAs, (2) a Rac1 small molecule inhibitor and (3) expression of a dominant negative mutant Rac1T17N. In addition, one of the well-known Rac1 effector kinases, Pak1, was also among the NDVsensitizing hits in the primary siRNA-based screening. Most importantly and in great contrast to oncogenic H-Ras, overexpression of Rac1wt directly rendered the resistant, non-tumorigenic HaCaT cells susceptible to NDV. Preliminary experiments with other NDVsusceptible human tumor cell lines with activating Ras mutations indicate that the requirement of Rac1 for the replication of oncolytic NDV is not limited to the model system used in this study (Supplementary Figure S4) .
Moreover, in our experimental setting of human keratinocytes the expression of Rac1T17N in RT3 K1 cells led to an inhibition of anchorage-independent growth, indicating that Rac1 is involved in the maintenance of autonomous growth behavior in these Rastransformed cells. We note that the effect of Rac1T17N on colony formation is stronger than the effect on NDV infectability indicating that these effects may result from different downstream effector pathways of Rac1.
In our experimental setting of keratinocytes, we observe an increased steady-state protein level of Rac1 in RT3 and RT3 K1 cells compared with HaCaT cells (Supplementary Figure S3) . On RNA level, there is no tumor-specific overexpression of Rac1 or the tumor associated, constantly activated splice variant Rac1b (Singh et al., 2004) (Supplementary Figure S3) . Naturally occurring activating mutations of Rac1 have not been found in tumors.
In summary, we provide strong evidence that oncogenic H-Ras, originally used to transform the non-tumorigenic HaCaT cells was essential for virus replication in the tumorigenic HaCaT cells (RT3 K1). However, Ras was not sufficient to render the nonsusceptible HaCaT cells permissive for NDV. By performing an siRNA-based screen to reveal tumorrelated virus-sensitizing genes the Rho GTPase Rac1 was found. Moreover, in contrast to activated Ras, transfection of Rac1wt directly induced NDV-susceptibility in non-tumorigenic HaCaT cells, thus demonstrating that Rac1 rather than Ras is the essential player in this scenario.
More generally, the described screening approach, which uses oncolytic virus replication in tumor cells and corresponding non-transformed cells, could provide a basis for the identification of novel tumor-associated clinical targets as well as biomarkers for oncolytic virus replication.
Materials and methods

See Supplementary information for Materials and methods.
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